RhumbLine Advisers
TVRD

RhumbLine Advisers’s Tvardi Therapeutics TVRD Stock Holding History

RhumbLine Advisers’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.3K Buy
3,244
+118
+4% +$462 ﹤0.01% 3804
2025
Q4 		$13.4K Sell
3,126
-856
-21% -$7.67K ﹤0.01% 3818
2025
Q3 		$155K Buy
3,982
+571
+17% +$16.3K ﹤0.01% 3351
2025
Q2 		$79.6K Buy
+3,411
New +$80.7K ﹤0.01% 3592
2024
Q3 		– Sell
-852
Closed -$7.91K – 4357
2024
Q2 		$7.91K Sell
852
-1,285
-60% -$30.7K ﹤0.01% 4015
2024
Q1 		$70K Buy
2,137
+88
+4% +$2.28K ﹤0.01% 3543
2023
Q4 		$54.8K Sell
2,049
-60
-3% -$2.48K ﹤0.01% 3615
2023
Q3 		$128K Sell
2,109
-20
-0.9% -$1.88K ﹤0.01% 3376
2023
Q2 		$217K Sell
2,129
-2,171
-50% -$299K ﹤0.01% 3205
2023
Q1 		$760K Buy
4,300
+234
+6% +$78.4K ﹤0.01% 2250
2022
Q4 		$1.57M Buy
4,066
+29
+0.7% +$11K ﹤0.01% 1912
2022
Q3 		$1.36M Buy
4,037
+247
+7% +$89.5K ﹤0.01% 1978
2022
Q2 		$1.25M Buy
3,790
+180
+5% +$63.1K ﹤0.01% 2036
2022
Q1 		$1.58M Buy
3,610
+2
+0.1% +$821 ﹤0.01% 1928
2021
Q4 		$1.58M Sell
3,608
-29
-0.8% -$14.6K ﹤0.01% 2004
2021
Q3 		$2.02M Sell
3,637
-497
-12% -$249K ﹤0.01% 1903
2021
Q2 		$2.12M Buy
4,134
+2,646
+178% +$1.68M ﹤0.01% 1923
2021
Q1 		$1.16M Sell
1,488
-96
-6% -$65.7K ﹤0.01% 2136
2020
Q4 		$863K Buy
1,584
+60
+4% +$31.5K ﹤0.01% 2207
2020
Q3 		$698K Sell
1,524
-230
-13% -$134K ﹤0.01% 2139
2020
Q2 		$1.08M Buy
1,754
+121
+7% +$66.8K ﹤0.01% 2011
2020
Q1 		$777K Sell
1,633
-66
-4% -$35.9K ﹤0.01% 1991
2019
Q4 		$986K Buy
1,699
+137
+9% +$96.1K ﹤0.01% 2094
2019
Q3 		$1.03M Buy
1,562
+145
+10% +$121K ﹤0.01% 2025
2019
Q2 		$1.1M Buy
1,417
+124
+10% +$87.1K ﹤0.01% 2023
2019
Q1 		$913K Buy
1,293
+69
+6% +$41.3K ﹤0.01% 2080
2018
Q4 		$573K Buy
1,224
+444
+57% +$286K ﹤0.01% 2230
2018
Q3 		$673K Buy
780
+39
+5% +$28.2K ﹤0.01% 2168
2018
Q2 		$511K Buy
741
+38
+5% +$19.3K ﹤0.01% 2305
2018
Q1 		$313K Sell
703
-22
-3% -$10.7K ﹤0.01% 2413
2017
Q4 		$320K Sell
725
-136
-16% -$62K ﹤0.01% 2439
2017
Q3 		$424K Buy
861
+13
+2% +$6.51K ﹤0.01% 2393
2017
Q2 		$470K Buy
848
+121
+17% +$76.8K ﹤0.01% 2335
2017
Q1 		$481K Buy
727
+22
+3% +$11.8K ﹤0.01% 2269
2016
Q4 		$236K Buy
705
+27
+4% +$8.66K ﹤0.01% 2605
2016
Q3 		$204K Sell
678
-239
-26% -$51.8K ﹤0.01% 2669
2016
Q2 		$159K Buy
917
+388
+73% +$84.5K ﹤0.01% 2823
2016
Q1 		$118K Buy
529
+10
+2% +$2.99K ﹤0.01% 2867
2015
Q4 		$315K Buy
519
+69
+15% +$37.9K ﹤0.01% 2550
2015
Q3 		$232K Buy
450
+56
+14% +$37.5K ﹤0.01% 2701
2015
Q2 		$172K Buy
+394
New +$152K ﹤0.01% 2932

Other funds holding TVRD

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return

RhumbLine Advisers's TVRD Position: Q1 2026 in Review

RhumbLine Advisers increased its Tvardi Therapeutics (TVRD) stake by 3.8% in Q1 2026, buying an estimated $462 and bringing the position to 3,244 shares worth $10.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3804.

RhumbLine Advisers first reported a position in TVRD in Q2 2015 and has held it in 41 quarters since. The position peaked at $2.12M in Q2 2021. 67 funds tracked by Wall St. Rank hold TVRD as of Q1 2026.

  • RhumbLine Advisers held 3,244 shares of Tvardi Therapeutics worth $10.3K as of Q1 2026.
  • RhumbLine Advisers bought 118 Tvardi Therapeutics shares in Q1 2026, an estimated $462.
  • Tvardi Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #3804 holding.
  • RhumbLine Advisers first reported a position in Tvardi Therapeutics in Q2 2015 and has held it in 41 quarters since.
  • RhumbLine Advisers's Tvardi Therapeutics position peaked at $2.12M in Q2 2021.
  • 67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.